Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Endocrinology · Gastrinoma

The Two Types of Gastrinoma: Sporadic vs. MEN1

At a Glance

Gastrinomas may be sporadic, often a single tumor in the pancreas or duodenum, or linked to inherited MEN1, which can cause many tiny duodenal tumors. The distinction guides genetic testing, surgery, surveillance, and family evaluation.

To understand your diagnosis, it helps to look at the “blueprints” of the tumor itself. While all gastrinomas cause the same high-acid symptoms, they fall into two distinct biological categories: sporadic (randomly occurring) or MEN1-associated (part of a genetic syndrome) [1]. Identifying which type you have is the most important step in planning your long-term care, as the surgical approach and monitoring for each are fundamentally different [2][3].

The Gastrinoma Triangle

Almost all gastrinomas develop within a specific anatomical area called the gastrinoma triangle [4]. This “hot zone” is bounded by the top of the pancreas, the duodenum (the first part of the small intestine), and the bile ducts [4].

Biologically, these tumors arise from neuroendocrine cells, which are unique because they behave like both nerve cells and hormone-producing gland cells [5]. When these cells within the triangle begin to multiply uncontrollably, they pump out gastrin, leading to the symptoms you are experiencing [6].

Sporadic vs. MEN1: Two Different Paths

The main difference between these two types lies in how the tumors form and where they are located.

Sporadic Gastrinoma

  • Single Target: These are usually solitary, meaning there is only one tumor mass [7].
  • Location: They are more likely than MEN1 cases to be found in the pancreas itself, though duodenal tumors still occur [8].
  • Spread: At the time of diagnosis, sporadic tumors are often evaluated for potential spread to the liver [1].
  • Surgical Goal: Because there is usually just one tumor, the goal is often “curative-intent” surgery to remove the mass entirely [9].

MEN1-Associated Gastrinoma

  • Genetic Cause: This type is caused by an inherited mutation in the MEN1 gene, which normally produces a protein called menin that keeps tumors from growing [10].
  • Multiple and Tiny: Instead of one large tumor, MEN1 often involves dozens or even hundreds of microscopic tumors scattered throughout the duodenal wall [1][11]. This is called being multicentric [8].
  • Other Neighbors: People with MEN1 often develop other tumors, most commonly in the parathyroid glands (causing high blood calcium) and the pituitary gland [1][12]. Note: Normal calcium levels do not rule out MEN1; germline genetic testing is the appropriate way to evaluate the syndrome.
  • Management: Because the tumors are so numerous and tiny, removing them all is difficult. Doctors often focus on active surveillance and only operate based on individualized multidisciplinary decisions. A tumor reaching a certain size (often 2 cm) is a commonly used risk threshold, but not an absolute rule [13][3].

Growth and Survival

Despite these biological differences, both types of well-differentiated tumors tend to grow very slowly [14]. While MEN1-associated gastrinomas tend to spread to the lymph nodes quite early—even when the tumors are tiny—this does not always mean the disease will become aggressive [15].

Survival estimates vary substantially by stage, tumor grade, and whether the disease has spread to the liver, so prognosis must be highly individualized [1]. The key is differentiating them early: a patient with localized sporadic disease might head straight to surgery, while a patient with MEN1 might first need their high calcium levels treated or a more conservative “active surveillance” plan for their digestive tumors [13][2].

Common questions in this guide

What is the difference between sporadic and MEN1-associated gastrinoma?
A sporadic gastrinoma is usually a single tumor and is more likely to arise in the pancreas, although it can occur in the duodenum. MEN1-associated gastrinoma is linked to an inherited MEN1 gene mutation and often involves many tiny tumors in the duodenal wall.
How can I find out whether my gastrinoma is linked to MEN1?
Germline genetic testing is the appropriate way to evaluate for MEN1. Calcium and parathyroid testing can provide useful clues, but a normal calcium level does not rule out MEN1.
Where do gastrinomas usually develop?
Most gastrinomas develop in an area called the gastrinoma triangle, which includes the duodenum, the head of the pancreas, and the nearby bile ducts. Imaging helps determine whether there is one tumor or multiple small tumors.
Does an MEN1-associated gastrinoma always require surgery?
Not always. Because MEN1 can cause numerous tiny tumors, doctors may recommend active surveillance and individualized decisions by a multidisciplinary team; a size around 2 centimeters is often considered a risk threshold, but it is not an automatic rule.
Can a small MEN1-associated gastrinoma spread to the lymph nodes?
Yes, MEN1-associated gastrinomas can involve nearby lymph nodes even when the primary tumors are small. Lymph-node spread does not by itself prove that the disease will behave aggressively, so prognosis also depends on tumor grade, stage, and whether the liver is involved.
Should my relatives be tested for MEN1?
If genetic testing identifies an MEN1 mutation, close relatives may benefit from genetic counseling and targeted testing. Their healthcare professionals can explain who should be tested and what screening would be appropriate if a mutation is found.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Have we ruled out MEN1 syndrome through germline genetic testing, or should we check my calcium and parathyroid levels first?
  2. 2.Is my tumor located in the 'gastrinoma triangle' (the duodenum or the head of the pancreas)?
  3. 3.Does my imaging show a single tumor or multiple small spots, and how does that affect my surgical options?
  4. 4.If I have MEN1, how do we decide when the risk of the tumor outweighs the risks of a major surgery?
  5. 5.What are the chances that this has already spread to my lymph nodes, even if the primary tumor is small?
  6. 6.Should my family members be tested for the MEN1 gene mutation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    [Comparison of clinical characteristics between sporadic gastrinoma and multiple endocrine neoplasia type 1-related gastrinoma].

    Guo Y, Chen LH, Liu M, et al.

    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery 2021; (24(10)):875-882 doi:10.3760/cma.j.cn.441530-20210719-00291.

    PMID: 34674462
  2. 2

    Gastrinomas: Medical or Surgical Treatment.

    Norton JA, Foster DS, Ito T, Jensen RT

    Endocrinology and metabolism clinics of North America 2018; (47(3)):577-601 doi:10.1016/j.ecl.2018.04.009.

    PMID: 30098717
  3. 3

    Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG).

    van Beek DJ, Nell S, Pieterman CRC, et al.

    Journal of surgical oncology 2019; (120(6)):966-975 doi:10.1002/jso.25667.

    PMID: 31401809
  4. 4

    MENIN-mediated regulation of gastrin gene expression and its role in gastrinoma development.

    Elvis-Offiah UB, Duan S, Merchant JL

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2023; (37(5)):e22913 doi:10.1096/fj.202201809RR.

    PMID: 37078545
  5. 5

    Sporadic Zollinger-Ellison syndrome in a patient with isolated mesenteric gastrinoma.

    Efared B, Tassiou EIM, Bako ABA, et al.

    International journal of surgery case reports 2024; (116()):109474 doi:10.1016/j.ijscr.2024.109474.

    PMID: 38447521
  6. 6

    Diagnosis and management of Zollinger-Ellison syndrome in 2018.

    De Angelis C, Cortegoso Valdivia P, Venezia L, et al.

    Minerva endocrinologica 2018; (43(2)):212-220 doi:10.23736/S0391-1977.17.02745-6.

    PMID: 28949124
  7. 7

    Recurrence after surgical resection of nonmetastatic sporadic gastrinoma: Which prognostic factors and surgical procedure?

    Robin L, Sauvanet A, Walter T, et al.

    Surgery 2023; (173(5)):1144-1152 doi:10.1016/j.surg.2022.12.030.

    PMID: 36781315
  8. 8

    How to treat gastrinomas in patients with multiple endocrine neoplasia type1: surgery or long-term proton pump inhibitors?

    Imamura M, Komoto I, Taki Y

    Surgery today 2023; (53(12)):1325-1334 doi:10.1007/s00595-022-02627-z.

    PMID: 36473964
  9. 9

    The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

    Guarnotta V, Martini C, Davì MV, et al.

    Endocrine 2018; (60(1)):15-27 doi:10.1007/s12020-017-1420-4.

    PMID: 29019150
  10. 10

    Clinically Defined Mutations in MEN1 Alter Its Tumor-suppressive Function Through Increased Menin Turnover.

    Duan S, Sheriff S, Elvis-Offiah UB, et al.

    Cancer research communications 2023; (3(7)):1318-1334 doi:10.1158/2767-9764.CRC-22-0522.

    PMID: 37492626
  11. 11

    Gastric enterochromaffin-like cell changes in multiple endocrine neoplasia type 1.

    Manoharan J, Anlauf M, Albers MB, et al.

    Clinical endocrinology 2021; (95(3)):439-446 doi:10.1111/cen.14430.

    PMID: 33506527
  12. 12

    Impact of Delay in Diagnosis in Outcomes in MEN1: Results From the Dutch MEN1 Study Group.

    van Leeuwaarde RS, van Nesselrooij BP, Hermus AR, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(3)):1159-65 doi:10.1210/jc.2015-3766.

    PMID: 26751192
  13. 13

    Surgical management of Zollinger-Ellison syndrome: Classical considerations and current controversies.

    Shao QQ, Zhao BB, Dong LB, et al.

    World journal of gastroenterology 2019; (25(32)):4673-4681 doi:10.3748/wjg.v25.i32.4673.

    PMID: 31528093
  14. 14

    Diagnosis and Management of Gastrointestinal Neuroendocrine Neoplasms.

    Gonzalez RS

    Surgical pathology clinics 2020; (13(3)):377-397 doi:10.1016/j.path.2020.04.002.

    PMID: 32773190
  15. 15

    Surgical Management of Zollinger-Ellison Syndrome in Multiple Endocrine Neoplasia Type 1 an AFCE and GTE Cohort Study. (Association Francophone de Chirurgie Endocrinienne and Groupe d'étude des Tumeurs Endocrines).

    Gaujoux S, Pattou F, Cadiot G, et al.

    World journal of surgery 2026; (50(5)):1300-1311 doi:10.1002/wjs.70303.

    PMID: 41862416

This page explains how sporadic and MEN1-associated gastrinomas can differ for educational purposes and does not replace medical advice. Discuss genetic testing, imaging, surgery, and surveillance with your care team.

Get notified when new evidence is published on pancreatic gastrinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.